WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces the reception of three esteemed International Organization for Standardization (ISO) certifications at its Ireland facility. These certifications include ISO 50001 for Energy Management Systems, ISO 14001 for Environmental Management Systems, and ISO 45001 for Occupational Health and Safety Management Systems. Achieving compliance with these rigorous global standards underscores the company’s unwavering dedication to Environmental, Social, and Governance (ESG) principles, highlighting its exceptional performance in environmental stewardship, sustainable energy management, and ensuring the health and safety of its workforce.
The ISO 50001 and ISO 14001 certifications particularly recognize the Ireland site’s remarkable efforts in reducing energy consumption and emissions. Noteworthy accomplishments in 2023 include transitioning to a power supply sourced entirely from renewable energy, alongside significant reductions of 1.7 GWh in electricity usage and 3.4 GWh in natural gas consumption. The facility has consistently pursued initiatives to minimize its environmental footprint, implementing various waste reduction strategies. Furthermore, it has prioritized employee well-being by implementing comprehensive Environment, Health, and Safety (EHS) programs aligned with ISO 45001 standards, ensuring a secure and healthy work environment.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee, expresses his satisfaction with this milestone, stating, “The ISO certifications represent a significant achievement for our Ireland site and underscore WuXi Biologics’ steadfast commitment to ESG principles across all our operations. By attaining these certifications, we assure our clients of our operational excellence and dedication to creating value for all stakeholders. This accomplishment also reinforces our pioneering role in promoting sustainability for the betterment of society.”
WuXi Biologics, listed under stock code 2269.HK, stands as a leading global CRDMO, offering comprehensive solutions for the discovery, development, and manufacturing of biologics, with a focus on improving patient outcomes worldwide. With a workforce of over 12,000 skilled professionals spanning China, the United States, Ireland, Germany, and Singapore, the company leverages its advanced technologies and expertise to deliver efficient and cost-effective biologics solutions from concept to commercialization. As of December 31, 2023, WuXi Biologics is actively supporting 698 integrated client projects, including 24 in the realm of commercial manufacturing.
WuXi Biologics is deeply committed to its Environmental, Social, and Governance (ESG) responsibilities, considering them fundamental to its ethos and business strategy. The company endeavors to emerge as an ESG leader within the biologics CRDMO sector. Its facilities incorporate next-generation biomanufacturing technologies and prioritize the use of clean energy sources. Additionally, an ESG committee, led by the CEO, has been established to steer the comprehensive ESG strategy and its implementation, further strengthening the company’s commitment to sustainability.
